Gilenia's Risk Management Should Key On Initial Doctor Visit, Cmte. Says
Executive Summary
Novartis' Risk Evaluation and Mitigation Strategy for Gilenia (fingolimod) may need to include more explicit testing requirements instead of just the physician and patient education programs that the firm has proposed
You may also be interested in...
“Defensive REMS” May Be Needed To Appease Advisory Committees
Sponsors facing an FDA advisory committee should be prepared to discuss Risk Evaluation and Mitigation Strategies, even if FDA tells a company that a REMS need only have minimal elements or is not necessary, to avoid a negative vote, industry experts say.
“Defensive REMS” May Be Needed To Appease Advisory Committees
Sponsors facing an FDA advisory committee should be prepared to discuss Risk Evaluation and Mitigation Strategies, even if FDA tells a company that a REMS need only have minimal elements or is not necessary, to avoid a negative vote, industry experts say.
Novartis' Gilenya: Efficacy, Patient Assistance Lie At Heart Of Marketing Push
As Novartis' multiple sclerosis treatment Gilenya (fingolimod) hits the market, the company is hoping to move beyond the fact that the drug is the first-ever oral drug for general treatment for the disease and highlight its clinical efficacy compared with other MS drugs.